Figure 1. Anti-VEGF vs Multi-angiokinase inhibition of CRC. Bevacizumab sensitive (left) and resistance (middle) responses are depicted, together with Nintedanib effects (right) on CRC tumor cells and vasculature. Resistance pathways (black); inhibited pathways (red).
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
